Cite
MLA Citation
J Weberpals et al.. “3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations.” International journal of gynecological cancer, vol. 30, n.d., pp. A2–A3. http://access.bl.uk/ark:/81055/vdc_100144717842.0x00001c